NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/07/2026
Voltar para busca
Dado oficial do USPTO
VVVVVVVV VEDA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
21/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
42
Data de depósito
27/02/2024
Data de registro
21/07/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/07/2026
Última transação
21/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2024-07-00
Primeiro uso no comércio
2024-07-00
Código do desenho
3
Tipo de titular
03
Localização do titular
Frederick, MD, US
Examinador
DETMER, CAROLYN ROSE
Unidade examinadora
N90
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized drawing of a starburst wherein the border is comprised of eight stylized "V" letters, the the left of the stylized word "VEDA".
Titulares e representantes
Titulares
Veda Life Sciences, Inc.
Representantes
Elizabeth Oliner Crandon Law
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Platform as a service (PAAS) featuring computer software platforms for use in providing back-end automation features to assist in onboarding new clinical trial sites and healthcare providers for facilitating and enabling recruitment of participants for use in runningmanaging and analyzing clinical trialsnamely enabling providers to create and scale clinical research capabilities and bring scientific advancements to patients that need them most; Platform as a service (PAAS) featuring computer software platforms for management and/or participation in clinical research in the nature of database creation and selecting configurable data collection methods with configurable optionsconfiguring a participant- facing website to recruit and screen participants for eligibility; Platform as a service (PAAS) featuring computer software platforms for automating workflows around patient communicationdata entryregulatory management and clinical trial operations use in facilitating and managing compliance and enabling preparation of new study trial sites for use in bringing trained clinical research coordinators together with community managers to run clinical trials at scale; Providing a website featuring online non-downloadable software for engaging community based healthcare organizations and clinical trial sponsors for use in clinical research analyticsdata capture formsmanagementviewing data analyticsenabling site data capture; selecting configurable data collection methods with configurable optionsconfiguring a participant- facing website to recruit and screen participants for eligibility; Platform as a service (PAAS) featuring computer software platforms for automating workflows around patient communicationdata entryregulatory management and clinical trial operations use in facilitating and managing compliance and enabling preparation of new study trial sites for use in bringing trained clinical research coordinators together with community managers to run clinical trials at scale; Providing a website featuring online non-downloadable software for engaging community- based healthcare organizations and clinical trial sponsors for use in clinical research analyticsdata capture formselectronic clinical outcome assessmentrecruitmentelectronic consent; Providing information in the field of clinical research via a website; Providing scientific research information in the field of clinical trials; Consulting services for others in the field of designplanningimplementation project management of clinical trials; none of the foregoing comprised of or consisting of the provision of healthcare or telehealth servicesscheduling healthcare or telehealth appointmentsallowing a patient to access personal healthcare information for the provision of healthcare or telehealth services
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
21/07/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
30/06/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
30/06/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/06/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/06/2026
IUAF
USE AMENDMENT FILED
18/02/2026
EISU
TEAS STATEMENT OF USE RECEIVED
18/02/2026
CHPB
POST PUBLICATION AMENDMENT - ENTERED
21/01/2026
APET
ASSIGNED TO PETITION STAFF
13/01/2026
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
30/12/2025
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
13/11/2025
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
08/11/2025
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
28/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/05/2025
PUBO
PUBLISHED FOR OPPOSITION
06/05/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/03/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
29/03/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
24/02/2025
GNFR
FINAL REFUSAL E-MAILED
24/02/2025
CNFR
FINAL REFUSAL WRITTEN
24/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/12/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
19/09/2024
GNRT
NON-FINAL ACTION E-MAILED
19/09/2024
CNRT
NON-FINAL ACTION WRITTEN
19/09/2024
DOCK
ASSIGNED TO EXAMINER
16/09/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/07/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/07/2024
NWAP
NEW APPLICATION ENTERED
27/02/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VVVVVVVV VEDA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.